Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Leukemia

  Free Subscription


Articles published in Am J Hematol

Retrieve available abstracts of 185 articles:
HTML format
Text format



Single Articles


    January 2018
  1. CASSADAY RD, Stevenson PA, Wood BL, Becker PS, et al
    Description and Prognostic Significance of the Kinetics of Minimal Residual Disease Status in Adults with Acute Lymphoblastic Leukemia Treated with HyperCVAD.
    Am J Hematol. 2018 Jan 10. doi: 10.1002/ajh.25030.
    PubMed     Text format     Abstract available


  2. ARAI Y, Kondo T, Shigematsu A, Tanaka J, et al
    Improved prognosis with additional medium-dose VP16 to CY/TBI in allogeneic transplantation for high risk ALL in adults.
    Am J Hematol. 2018;93:47-57.
    PubMed     Text format     Abstract available


    December 2017
  3. ASSI R, Ravandi F
    FLT3 Inhibitors in Acute Myeloid Leukemia: Choosing the Best when the Optimal Does Not Exist.
    Am J Hematol. 2017 Dec 29. doi: 10.1002/ajh.25027.
    PubMed     Text format     Abstract available


  4. DECROOCQ J, Itzykson R, Vigouroux S, Michallet M, et al
    Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Societe Francophone de Greffe de Moelle et de Therapie Cel
    Am J Hematol. 2017 Dec 11. doi: 10.1002/ajh.25004.
    PubMed     Text format     Abstract available


  5. BAIN BJ
    Pure erythroid leukemia.
    Am J Hematol. 2017 Dec 11. doi: 10.1002/ajh.25005.
    PubMed     Text format    


  6. DINARDO CD, Rausch CR, Benton C, Kadia T, et al
    Clinical Experience with the BCL2-inhibitor Venetoclax in Combination Therapy for Relapsed and Refractory Acute Myeloid Leukemia and Related Myeloid Malignancies.
    Am J Hematol. 2017 Dec 8. doi: 10.1002/ajh.25000.
    PubMed     Text format     Abstract available


  7. TROUSSARD X, Cornet E
    Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment.
    Am J Hematol. 2017;92:1382-1390.
    PubMed     Text format     Abstract available


  8. CHAPIRO E, Lesty C, Gabillaud C, Durot E, et al
    "Double-hit" chronic lymphocytic leukemia: An aggressive subgroup with 17p deletion and 8q24 gain.
    Am J Hematol. 2017 Dec 1. doi: 10.1002/ajh.24990.
    PubMed     Text format     Abstract available


  9. MOLICA M, Canichella M, Alunni Fegatelli D, Colafigli G, et al
    The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials.
    Am J Hematol. 2017;92:E661-E664.
    PubMed     Text format    


  10. KOBAYASHI T, Nannya Y, Ichikawa M, Oritani K, et al
    A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study).
    Am J Hematol. 2017;92:1324-1332.
    PubMed     Text format     Abstract available


    November 2017
  11. JABBOUR E, Dull J, Yilmaz M, Khoury JD, et al
    Outcome of Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia after Blinatumomab Failure: No Change in the Level of CD19 Expression.
    Am J Hematol. 2017 Nov 27. doi: 10.1002/ajh.24987.
    PubMed     Text format     Abstract available


  12. GODET S, Protin C, Dupuis J, Dartigeas C, et al
    Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French Innovative Leukemia Organization (FILO).
    Am J Hematol. 2017 Nov 22. doi: 10.1002/ajh.24981.
    PubMed     Text format    


  13. WALTER RB, Michaelis LC, Othus M, Uy GL, et al
    Intergroup LEAP Trial (S1612): A Randomized Phase 2/3 Platform Trial to Test Novel Therapeutics in Medically Less Fit Older Adults with Acute Myeloid Leukemia.
    Am J Hematol. 2017 Nov 22. doi: 10.1002/ajh.24980.
    PubMed     Text format    


  14. VENTON G, Courtier F, Charbonnier A, D'Incan E, et al
    Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms.
    Am J Hematol. 2017 Nov 17. doi: 10.1002/ajh.24973.
    PubMed     Text format     Abstract available


  15. ALTMAN JK, Foran JM, Pratz KW, Trone D, et al
    Phase 1 Study of Quizartinib in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.
    Am J Hematol. 2017 Nov 15. doi: 10.1002/ajh.24974.
    PubMed     Text format     Abstract available


  16. DEANGELO DJ, Brunner AM, Werner L, Avigan D, et al
    A Phase I Study of Lenalidomide plus Chemotherapy with Mitoxantrone, Etoposide, and Cytarabine for the Reinduction of Patients with Acute Myeloid Leukemia.
    Am J Hematol. 2017 Nov 9. doi: 10.1002/ajh.24968.
    PubMed     Text format     Abstract available


  17. CANAANI J, Savani BN, Labopin M, Huang XJ, et al
    Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation.
    Am J Hematol. 2017 Nov 8. doi: 10.1002/ajh.24963.
    PubMed     Text format     Abstract available


  18. SANDMAIER BM, Khaled S, Oran B, Gammon G, et al
    Results of a Phase 1 Study of Quizartinib as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Remission Following Allogeneic Hematopoietic Stem Cell Transplant.
    Am J Hematol. 2017 Nov 1. doi: 10.1002/ajh.24959.
    PubMed     Text format     Abstract available


    October 2017
  19. MINETTO P, Guolo F, Clavio M, Kunkl A, et al
    A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis.
    Am J Hematol. 2017 Oct 28. doi: 10.1002/ajh.24956.
    PubMed     Text format    


  20. COOMBS CC, Mathews SP
    Acute promyelocytic leukemia and chronic lymphocytic leukemia diagnosed concurrently.
    Am J Hematol. 2017 Oct 20. doi: 10.1002/ajh.24950.
    PubMed     Text format    


  21. ABAZA Y, Kantarjian HM, Faderl S, Jabbour E, et al
    Hyper-CVAD plus Nelarabine in Newly Diagnosed Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma.
    Am J Hematol. 2017 Oct 19. doi: 10.1002/ajh.24947.
    PubMed     Text format     Abstract available


  22. ALHURAIJI A, Kantarjian H, Boddu P, Ravandi F, et al
    Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors.
    Am J Hematol. 2017 Oct 13. doi: 10.1002/ajh.24943.
    PubMed     Text format     Abstract available


  23. KHODER A, Al Obaidi M, Wiles N, Nadal-Melsio E, et al
    Lymphoplasmacytoid cytology in plasma cell leukemia.
    Am J Hematol. 2017 Oct 13. doi: 10.1002/ajh.24940.
    PubMed     Text format    


  24. TEFFERI A, Hanson CA, Ketterling RP
    Revisiting the need for bone marrow examination in chronic myeloid leukemia.
    Am J Hematol. 2017 Oct 13. doi: 10.1002/ajh.24942.
    PubMed     Text format    


  25. PATNAIK MM, Vallapureddy R, Yalniz FF, Hanson CA, et al
    Therapy Related-Chronic Myelomonocytic Leukemia (CMML): Molecular, Cytogenetic and Clinical Distinctions from de novo CMML.
    Am J Hematol. 2017 Oct 11. doi: 10.1002/ajh.24939.
    PubMed     Text format     Abstract available


  26. IZZI V, Lakkala J, Devarajan R, Savolainen ER, et al
    Vanin 1 (VNN1) levels predict poor outcome in acute myeloid leukemia.
    Am J Hematol. 2017 Oct 3. doi: 10.1002/ajh.24925.
    PubMed     Text format    


  27. LAZAREVIC VL, Labopin M, Wu D, Yakoub-Agha I, et al
    Relatively favourable outcome after allogeneic stem cell transplantation for BCR-ABL1-positive AML: A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
    Am J Hematol. 2017 Oct 3. doi: 10.1002/ajh.24928.
    PubMed     Text format     Abstract available


  28. EL FAKIH R, Jabbour E, Ravandi F, Hassanein M, et al
    Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults.
    Am J Hematol. 2017 Oct 3. doi: 10.1002/ajh.24926.
    PubMed     Text format     Abstract available


  29. SPERR WR, Herndlhofer S, Gleixner K, Girschikofsky M, et al
    Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients >/=60 years.
    Am J Hematol. 2017;92:E567-E574.
    PubMed     Text format     Abstract available


  30. RASHIDI A, Linden MA, DeFor TE, Warlick E, et al
    History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission.
    Am J Hematol. 2017;92:1032-1036.
    PubMed     Text format     Abstract available


  31. SHIMONI A, Vago L, Bernardi M, Yerushalmi R, et al
    Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning.
    Am J Hematol. 2017;92:1011-1019.
    PubMed     Text format     Abstract available


  32. MOLOGNI L, Piazza R, Khandelwal P, Pirola A, et al
    Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients.
    Am J Hematol. 2017;92:E623-E625.
    PubMed     Text format    


  33. JAIN P, Burger JA, Khoury JD
    CLL progression after one cycle of FCR: Richter's transformation versus EBV-associated lympho-proliferation.
    Am J Hematol. 2017;92:1113-1114.
    PubMed     Text format    


    September 2017
  34. GAKSCH L, Kashofer K, Heitzer E, Quehenberger F, et al
    Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia.
    Am J Hematol. 2017 Sep 29. doi: 10.1002/ajh.24922.
    PubMed     Text format     Abstract available


  35. BRECCIA M, Colafigli G, Molica M, Scalzulli E, et al
    Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life.
    Am J Hematol. 2017 Sep 28. doi: 10.1002/ajh.24916.
    PubMed     Text format    


  36. HAMPEL PJ, Chaffee KG, King RL, Simonetto D, et al
    Liver Dysfunction in Chronic Lymphocytic Leukemia: Prevalence, Outcomes, and Pathological Findings.
    Am J Hematol. 2017 Sep 22. doi: 10.1002/ajh.24915.
    PubMed     Text format     Abstract available


  37. CHANG YJ, Zhao XS, Wang Y, Liu YR, et al
    Effects of Pre- and Post-transplantation Minimal Residual Disease on Outcomes in Pediatric Patients with Acute Myeloid Leukemia Receiving Human Leukocyte Antigen-matched or Mismatched Related Donor Allografts.
    Am J Hematol. 2017 Sep 20. doi: 10.1002/ajh.24910.
    PubMed     Text format    


  38. GORIN NC, Labopin M, Pabst T, Remenyi P, et al
    Unrelated matched versus autologous transplantation in adult patients with good and intermediate risk acute myelogenous leukemia in first molecular remission.
    Am J Hematol. 2017 Sep 11. doi: 10.1002/ajh.24904.
    PubMed     Text format     Abstract available


  39. HALLEK M
    Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
    Am J Hematol. 2017;92:946-965.
    PubMed     Text format     Abstract available


  40. PERERA LP, Zhang M, Nakagawa M, Petrus MN, et al
    Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies.
    Am J Hematol. 2017;92:892-901.
    PubMed     Text format     Abstract available


  41. BEHRENS M, Chowdry RP, Saba S, Saba NS, et al
    A centrocyte blood count of a quarter million.
    Am J Hematol. 2017;92:972-973.
    PubMed     Text format    


    August 2017
  42. SHI CR, Nambudiri VE
    Imatinib-induced psoriasiform eruption in a patient with chronic myeloid leukemia.
    Am J Hematol. 2017 Aug 24. doi: 10.1002/ajh.24894.
    PubMed     Text format    


  43. GOLDBERG SL, Cortes J, Gambacorti-Passerini C, Hehlmann R, et al
    First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
    Am J Hematol. 2017 Aug 17. doi: 10.1002/ajh.24887.
    PubMed     Text format     Abstract available


  44. COLTRO G, Mannelli F, Guglielmelli P, Pacilli A, et al
    A life-threatening ruxolitinib discontinuation syndrome.
    Am J Hematol. 2017;92:833-838.
    PubMed     Text format    


  45. YSEBAERT L, Aurran-Schleinitz T, Dartigeas C, Dilhuydy MS, et al
    Real-world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients.
    Am J Hematol. 2017;92:E166-E168.
    PubMed     Text format    


    July 2017
  46. BEGNA K, Al-Kali A, Elliott M, Foran J, et al
    Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey.
    Am J Hematol. 2017 Jul 21. doi: 10.1002/ajh.24866.
    PubMed     Text format    


  47. BAIN BJ
    Pure erythroid leukemia: the need gather data on this condition as defined in the World Health Organisation classification.
    Am J Hematol. 2017 Jul 13. doi: 10.1002/ajh.24863.
    PubMed     Text format    


  48. VALLAPUREDDY R, Lasho TL, Hoversten K, Finke CM, et al
    Nucleophosmin 1 (NPM1) Mutations in Chronic Myelomonocytic Leukemia and Their Prognostic Relevance.
    Am J Hematol. 2017 Jul 13. doi: 10.1002/ajh.24861.
    PubMed     Text format    


  49. WANG W, Wang S, Medeiros LJ, Khoury JD, et al
    Response to Dr. Bain's comment on our review article: Pure Erythroid Leukemia.
    Am J Hematol. 2017 Jul 13. doi: 10.1002/ajh.24862.
    PubMed     Text format    


  50. JAROSOVA M, Hruba M, Oltova A, Plevova K, et al
    Chromosome 6q deletion correlates with poor prognosis and low relative expression of FOXO3 in chronic lymphocytic leukemia patients.
    Am J Hematol. 2017 Jul 11. doi: 10.1002/ajh.24852.
    PubMed     Text format    


  51. KLIL-DRORI AJ, Yin H, Azoulay L, Harnois M, et al
    Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response.
    Am J Hematol. 2017 Jul 3. doi: 10.1002/ajh.24838.
    PubMed     Text format    


  52. RHEE SJ, Lee JW, Yu KS, Hong KT, et al
    Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.
    Am J Hematol. 2017;92:607-613.
    PubMed     Text format     Abstract available


    June 2017
  53. JAIN P, Kantarjian H, Jain N, Short NJ, et al
    Clinical characteristics and outcomes of previously untreated patients with adult onset T-ALL and T-lymphoblastic lymphoma (T-LL) with Hyper-CVAD based regimens.
    Am J Hematol. 2017 Jun 24. doi: 10.1002/ajh.24833.
    PubMed     Text format    


  54. LEVIN A, Kleman A, Rein L, Tarima S, et al
    Early Mortality in Patients with Acute Myelogenous Leukemia Treated in Teaching versus Non-teaching Hospitals: A Large Database Analysis.
    Am J Hematol. 2017 Jun 20. doi: 10.1002/ajh.24825.
    PubMed     Text format    


  55. EDER S, Canaani J, Beohou E, Labopin M, et al
    Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Socie
    Am J Hematol. 2017 Jun 14. doi: 10.1002/ajh.24823.
    PubMed     Text format     Abstract available


  56. TERRY CM, Shallis RM, Estey E, Lim SH, et al
    Day 14 bone marrow examination in the management of acute myeloid leukemia.
    Am J Hematol. 2017 Jun 13. doi: 10.1002/ajh.24818.
    PubMed     Text format     Abstract available


  57. BAZIN J, Karnik L, Tudor-Williams G, Kelly AM, et al
    Juvenile myelomonocytic leukemia in an infant with congenital HIV and CMV infection.
    Am J Hematol. 2017 Jun 13. doi: 10.1002/ajh.24815.
    PubMed     Text format    


  58. CROMBIE J, Davids MS
    IGHV Mutational Status Testing in Chronic Lymphocytic Leukemia.
    Am J Hematol. 2017 Jun 7. doi: 10.1002/ajh.24808.
    PubMed     Text format     Abstract available


  59. SALEM A, Loghavi S, Tang G, Huh YO, et al
    Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.
    Am J Hematol. 2017;92:520-528.
    PubMed     Text format     Abstract available


  60. MOLICA S, Giannarelli D, Mirabelli R, Levato L, et al
    Reliability of six prognostic models to predict time-to-first-treatment in patients with chronic lymphocytic leukaemia in early phase.
    Am J Hematol. 2017;92:E91-E93.
    PubMed     Text format    


  61. DE ROCCO D, Melazzini F, Marconi C, Pecci A, et al
    Mutations of RUNX1 in families with inherited thrombocytopenia.
    Am J Hematol. 2017;92:E86-E88.
    PubMed     Text format    


    May 2017
  62. RASHIDI A, Ali AM, Vij KR, Shanley R, et al
    Allogeneic hematopoietic cell transplantation in morphologic leukemia-free aplastic state.
    Am J Hematol. 2017 May 31. doi: 10.1002/ajh.24804.
    PubMed     Text format    


  63. JABBOUR E, Daver NG, Short NJ, Huang X, et al
    Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia.
    Am J Hematol. 2017 May 27. doi: 10.1002/ajh.24799.
    PubMed     Text format     Abstract available


  64. KONDO T, Nagamura-Inoue T, Tojo A, Nagamura F, et al
    Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia.
    Am J Hematol. 2017 May 20. doi: 10.1002/ajh.24793.
    PubMed     Text format     Abstract available


  65. ALDOSS I, Song J, Stiller T, Nguyen T, et al
    Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia.
    Am J Hematol. 2017 May 11. doi: 10.1002/ajh.24783.
    PubMed     Text format     Abstract available


  66. RAGON BK, Daver N, Garcia-Manero G, Ravandi F, et al
    Minimal Residual Disease Eradication with Epigenetic Therapy in Core Binding Factor Acute Myeloid Leukemia.
    Am J Hematol. 2017 May 11. doi: 10.1002/ajh.24782.
    PubMed     Text format     Abstract available


  67. GONCALVES MV, Rodrigues CA, Metze IGHL, Lacerda MP, et al
    Chronic lymphocytic leukemia in Brazil: A retrospective analysis of 1903 cases.
    Am J Hematol. 2017 May 5. doi: 10.1002/ajh.24779.
    PubMed     Text format    


  68. NANAH R, McCullough K, Hogan W, Begna K, et al
    Outcome of Elderly Patients after Failure to Hypomethylating Agents Given as Frontline Therapy for Acute Myeloid Leukemia (AML): Single Institution Experience.
    Am J Hematol. 2017 May 5. doi: 10.1002/ajh.24780.
    PubMed     Text format     Abstract available


  69. CASTAGNETTI F, Gugliotta G, Breccia M, Iurlo A, et al
    The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
    Am J Hematol. 2017 May 2. doi: 10.1002/ajh.24774.
    PubMed     Text format     Abstract available



  70. Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII.
    Am J Hematol. 2017;92:E85.
    PubMed     Text format    


    April 2017
  71. CANAANI J, Savani BN, Labopin M, Michallet M, et al
    ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia - a report from the acute leukemia working party of the EBMT.
    Am J Hematol. 2017 Apr 25. doi: 10.1002/ajh.24771.
    PubMed     Text format     Abstract available


  72. BHATT VR, Shostrom V, Giri S, Gundabolu K, et al
    Early Mortality and Overall Survival of Acute Myeloid Leukemia Based on Facility Type.
    Am J Hematol. 2017 Apr 24. doi: 10.1002/ajh.24767.
    PubMed     Text format     Abstract available


  73. LARSEN JT, Shanafelt TD, Leis JF, LaPlant B, et al
    Akt inhibitor MK-2206 in combination with Bendamustine and Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results from the N1087 Alliance Study.
    Am J Hematol. 2017 Apr 12. doi: 10.1002/ajh.24762.
    PubMed     Text format     Abstract available


  74. BAPTISTA MJ, Granada I, Morgades M, Calasanz MJ, et al
    Monosomal karyotype in chronic lymphocytic leukemia: association with clinical and biological features and potential prognostic significance.
    Am J Hematol. 2017 Apr 6. doi: 10.1002/ajh.24754.
    PubMed     Text format    


  75. REDA G, Cassin R, Fattizzo B, Giannarelli D, et al
    Chronic lymphocytic leukemia (CLL) and prognostic models: A bridge between clinical and biological markers.
    Am J Hematol. 2017 Apr 6. doi: 10.1002/ajh.24755.
    PubMed     Text format    


  76. SACHA T, Gora-Tybor J, Szarejko M, Bober G, et al
    A multicenter prospective study on efficacy and safety of imatinib generics; a report from Polish Adult Leukemia Group imatinib generics registry.
    Am J Hematol. 2017 Apr 4. doi: 10.1002/ajh.24748.
    PubMed     Text format     Abstract available


  77. YU Y, Zhang T, Wang Q, Wu D, et al
    Counting bone marrow blasts as a percentage of nonerythroid cells improves the prognostic evaluation of MDS with erythroid predominance.
    Am J Hematol. 2017;92:E55-E57.
    PubMed     Text format    


  78. PEMMARAJU N, Jain P, Medeiros LJ, Jorgenson JL, et al
    PET-positive lymphadenopathy in CLL-Not always Richter transformation.
    Am J Hematol. 2017;92:405-406.
    PubMed     Text format    


    March 2017
  79. WEINBERG OK, Gibson CJ, Blonquist TM, Neuberg D, et al
    NPM1 mutation but not RUNX1 mutation or multilineage dysplasia defines a prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytogenetic abnormalities in the revised 2016 WHO Classification.
    Am J Hematol. 2017 Mar 28. doi: 10.1002/ajh.24739.
    PubMed     Text format    


  80. CANAANI J, Labopin M, Socie G, Nihtinen A, et al
    Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: an analysis from the acute leukemia working party of the EBMT.
    Am J Hematol. 2017 Mar 28. doi: 10.1002/ajh.24737.
    PubMed     Text format     Abstract available


  81. KANTARJIAN HM, Schuster MW, Jain N, Advani A, et al
    A Phase 1 Study of AMG 900, an Orally Administered Pan-Aurora Kinase Inhibitor, in Adult Patients With Acute Myeloid Leukemia.
    Am J Hematol. 2017 Mar 28. doi: 10.1002/ajh.24736.
    PubMed     Text format     Abstract available


  82. ALFONSO A, Montalban-Bravo G, Takahashi K, Jabbour EJ, et al
    Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.
    Am J Hematol. 2017 Mar 28. doi: 10.1002/ajh.24735.
    PubMed     Text format     Abstract available


  83. KANDARPA M, Wu YM, Robinson D, Burke PW, et al
    Clinical Characteristics and Whole Exome/Transcriptome Sequencing of Coexisting Chronic Myeloid Leukemia and Myelofibrosis.
    Am J Hematol. 2017 Mar 23. doi: 10.1002/ajh.24728.
    PubMed     Text format     Abstract available


  84. PATNAIK MM, Barraco D, Lasho TL, Finke CM, et al
    Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia.
    Am J Hematol. 2017 Mar 17. doi: 10.1002/ajh.24722.
    PubMed     Text format     Abstract available


  85. SHORT NJ, Kantarjian HM, Ko H, Khoury JD, et al
    Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma.
    Am J Hematol. 2017 Mar 15. doi: 10.1002/ajh.24720.
    PubMed     Text format    


  86. MAURO FR, Galieni P, Tedeschi A, Laurenti L, et al
    Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma.
    Am J Hematol. 2017 Mar 10. doi: 10.1002/ajh.24714.
    PubMed     Text format     Abstract available


  87. MICHALLET AS, Campidelli A, Lequeu H, Dilhuydy MS, et al
    Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France A study from the French Innovative Leukemia Organization (FILO) group.
    Am J Hematol. 2017 Mar 10. doi: 10.1002/ajh.24715.
    PubMed     Text format    


  88. GRIFFIN PT, Komrokji RS, Sweet K, Al Ali NH, et al
    Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience.
    Am J Hematol. 2017;92:232-237.
    PubMed     Text format     Abstract available


    February 2017
  89. KAYA Z, Alici N, Ozmen OE, Akgul M, et al
    Identification of renal infiltration based on urinary findings in a child with burkitt leukemia/lymphoma.
    Am J Hematol. 2017 Feb 22. doi: 10.1002/ajh.24694.
    PubMed     Text format    


  90. DE MARCHI F, Candoni A, Zannier ME, Lau WY, et al
    Concomitant monitoring of WT1 and FLT3-ITD expression in FLT3-ITD Acute Myeloid Leukemia patients: which should we trust as a minimal residual disease marker?
    Am J Hematol. 2017 Feb 17. doi: 10.1002/ajh.24686.
    PubMed     Text format    


  91. HU Z, Medeiros LJ, Fang L, Sun Y, et al
    Prognostic Significance of Cytogenetic Abnormalities in T-Cell Prolymphocytic Leukemia.
    Am J Hematol. 2017 Feb 14. doi: 10.1002/ajh.24679.
    PubMed     Text format     Abstract available


  92. USTUN C, Williams S, Skendzel S, Kodal B, et al
    Allogeneic NK cells eradicate myeloblasts but not neoplastic mast cells in systemic mastocytosis associated with acute myeloid leukemia.
    Am J Hematol. 2017 Feb 10. doi: 10.1002/ajh.24673.
    PubMed     Text format    


  93. BORATE U, Norris BA, Lo P, Tognon C, et al
    Identification of targeted therapies for rare adult mature t-cell leukemia using functional ex vivo screening of primary patient samples.
    Am J Hematol. 2017 Feb 9. doi: 10.1002/ajh.24669.
    PubMed     Text format    


  94. SHOUVAL R, Bonifazi F, Fein J, Boschini C, et al
    Validation of the Acute Leukemia-EBMT score for prediction of mortality following allogeneic stem cell transplantation in a multi-center GITMO cohort.
    Am J Hematol. 2017 Feb 9. doi: 10.1002/ajh.24677.
    PubMed     Text format     Abstract available


  95. NAKASONE H, Fuji S, Yakushijin K, Onizuka M, et al
    Impact of total body irradiation on successful neutrophil engraftment in unrelated bone marrow or cord blood transplantation.
    Am J Hematol. 2017;92:171-178.
    PubMed     Text format     Abstract available


  96. DINARDO CD, Luskin MR, Carroll M, Smith C, et al
    Validation of a clinical assay of multi-locus DNA methylation for prognosis of newly diagnosed AML.
    Am J Hematol. 2017;92:E14-E15.
    PubMed     Text format    


    January 2017
  97. JENTZSCH M, Bill M, Nicolet D, Leiblein S, et al
    Prognostic Impact of the CD34+/CD38- Cell Burden in Patients with Acute Myeloid Leukemia receiving Allogeneic Stem Cell Transplantation.
    Am J Hematol. 2017 Jan 30. doi: 10.1002/ajh.24663.
    PubMed     Text format     Abstract available


  98. DELGADO J, Doubek M, Baumann T, Kotaskova J, et al
    Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.
    Am J Hematol. 2017 Jan 25. doi: 10.1002/ajh.24660.
    PubMed     Text format     Abstract available


  99. JAYAKAR V, Cheung K, Yebra-Fernandez E, Bain BJ, et al
    The distinctive cytological features of T-cell prolymphocytic leukemia.
    Am J Hematol. 2017 Jan 25. doi: 10.1002/ajh.24659.
    PubMed     Text format    


  100. PLUTA A, Robak T, Wrzesien-Kus A, Budziszewska BK, et al
    Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly AML patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial.
    Am J Hematol. 2017 Jan 19. doi: 10.1002/ajh.24654.
    PubMed     Text format     Abstract available


  101. FUJISAWA S, Mizuta S, Akiyama H, Ueda Y, et al
    Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.
    Am J Hematol. 2017 Jan 19. doi: 10.1002/ajh.24653.
    PubMed     Text format     Abstract available


  102. TIRIBELLI M, Geromin A, Damiani D
    Impact of fludarabine-based induction therapy on outcome of FLT3-/NPM1+ cytogenetically normal acute myeloid leukemia.
    Am J Hematol. 2017 Jan 11. doi: 10.1002/ajh.24651.
    PubMed     Text format    


  103. WEINBERG OK, Sohani AR, Bhargava P, Nardi V, et al
    Diagnostic Work-up of Acute Myeloid Leukemia.
    Am J Hematol. 2017 Jan 9. doi: 10.1002/ajh.24648.
    PubMed     Text format     Abstract available


  104. GABALLA S, Saliba R, Oran B, Brammer JE, et al
    Relapse Risk and Survival in Patients with FLT3 Acute Myeloid Leukemia Undergoing Stem Cell Transplantation.
    Am J Hematol. 2017 Jan 4. doi: 10.1002/ajh.24632.
    PubMed     Text format     Abstract available


  105. PEMMARAJU N, Kantarjian H, Jorgensen JL, Jabbour E, et al
    Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission.
    Am J Hematol. 2017 Jan 4. doi: 10.1002/ajh.24629.
    PubMed     Text format     Abstract available


  106. CANAANI J, Beohou E, Labopin M, Socie G, et al
    Impact of FAB Classification on Predicting Outcome in Acute Myeloid Leukemia, Not Otherwise Specified, Patients Undergoing Allogeneic Stem Cell Transplantation in CR1: An Analysis of 1690 Patients from the Acute Leukemia Working Party of EBMT.
    Am J Hematol. 2017 Jan 4. doi: 10.1002/ajh.24640.
    PubMed     Text format     Abstract available


  107. TEFFERI A, Barbui T
    Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2017;92:94-108.
    PubMed     Text format     Abstract available


  108. RAGON BK, Kantarjian H, Jabbour E, Ravandi F, et al
    Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias.
    Am J Hematol. 2017;92:7-11.
    PubMed     Text format     Abstract available


  109. JAIN P, Kantarjian H, Jabbour E, Kanagal-Shamanna R, et al
    Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias-(De novo and blast phase CML).
    Am J Hematol. 2017;92:E3-E4.
    PubMed     Text format    


  110. JAIN P, Nagarajan P, Prayag P, Benton CB, et al
    Mixed angioinvasive exserohilum and scedosporium infection in a patient with AML.
    Am J Hematol. 2017;92:119-120.
    PubMed     Text format    


    December 2016
  111. WANG W, Wang SA, Medeiros LJ, Khoury JD, et al
    Pure Erythroid Leukemia.
    Am J Hematol. 2016 Dec 22. doi: 10.1002/ajh.24626.
    PubMed     Text format     Abstract available


  112. SHORT NJ, Kantarjian HM, Sasaki K, Ravandi F, et al
    Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor.
    Am J Hematol. 2016 Dec 22. doi: 10.1002/ajh.24625.
    PubMed     Text format     Abstract available


    November 2016
  113. PINNIX CC, Chi L, Jabbour EJ, Milgrom SA, et al
    Dorsal Column Myelopathy after Intrathecal Chemotherapy for Leukemia.
    Am J Hematol. 2016 Nov 22. doi: 10.1002/ajh.24611.
    PubMed     Text format     Abstract available


  114. ALDOSS I, Stiller T, Song J, AlMalki M, et al
    Philadelphia chromosome as a recurrent event among therapy-related acute leukemia.
    Am J Hematol. 2016 Nov 10. doi: 10.1002/ajh.24604.
    PubMed     Text format    


  115. WINESTONE LE, Getz KD, Miller TP, Wilkes JJ, et al
    The Role of Acuity of Illness at Presentation in Early Mortality in Black Children with Acute Myeloid Leukemia.
    Am J Hematol. 2016 Nov 10. doi: 10.1002/ajh.24605.
    PubMed     Text format     Abstract available


  116. BAIN BJ
    Early leukemic transformation of adult T-cell leukemia/lymphoma presenting as meningeal lymphoma.
    Am J Hematol. 2016 Nov 8. doi: 10.1002/ajh.24602.
    PubMed     Text format    


  117. SAYAR H, Bashardoust P, Cripe L, Chakraborty S, et al
    Long-term outcome of NPM1 mutated acute myeloid leukemia: A single-institution experience.
    Am J Hematol. 2016 Nov 4. doi: 10.1002/ajh.24601.
    PubMed     Text format    


    October 2016
  118. CASTAGNETTI F, Di Raimondo F, De Vivo A, Spitaleri A, et al
    A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.
    Am J Hematol. 2016 Oct 22. doi: 10.1002/ajh.24591.
    PubMed     Text format     Abstract available


  119. NABHAN C, Mato AR, Feinberg BA
    Clinical Pathways in Chronic lymphocytic Leukemia: Challenges and Solutions.
    Am J Hematol. 2016 Oct 20. doi: 10.1002/ajh.24589.
    PubMed     Text format    


  120. RAESS PW, Cascio MJ, Fan G, Press R, et al
    Concurrent STAT3, DNMT3A and TET2 mutations in T-LGL leukemia with molecularly distinct clonal hematopoiesis of indeterminate potential.
    Am J Hematol. 2016 Oct 19. doi: 10.1002/ajh.24586.
    PubMed     Text format    


  121. GREENER D, Henrichs KF, Liesveld JL, Heal JM, et al
    Improved Outcomes in Acute Myeloid Leukemia Patients Treated with Washed Transfusions.
    Am J Hematol. 2016 Oct 19. doi: 10.1002/ajh.24585.
    PubMed     Text format    


  122. PATNAIK MM, Barraco D, Lasho TL, Finke CM, et al
    DNMT3A Mutations are Associated with Inferior Overall and Leukemia-free Survival in Chronic Myelomonocytic Leukemia.
    Am J Hematol. 2016 Oct 12. doi: 10.1002/ajh.24581.
    PubMed     Text format     Abstract available


  123. HU Z, Sun Y, Wang W, Medeiros LJ, et al
    Refractory Hairy Cell Leukemia-Variant.
    Am J Hematol. 2016 Oct 11. doi: 10.1002/ajh.24580.
    PubMed     Text format    


  124. ROSKO A, Wang HL, de Lima M, Sandmaier B, et al
    Reduced Intensity Conditioned Allograft Yields Favorable Survival for Older Adults with B-cell Acute Lymphoblastic Leukemia.
    Am J Hematol. 2016 Oct 6. doi: 10.1002/ajh.24575.
    PubMed     Text format     Abstract available


    September 2016
  125. LI R, Hu X, Wang L, Cheng H, et al
    Fludarabine and Cytarabine versus High-dose Cytarabine in Consolidation Treatment of t(8; 21) Acute Myeloid Leukemia: a prospective, randomized study.
    Am J Hematol. 2016 Sep 27. doi: 10.1002/ajh.24569.
    PubMed     Text format     Abstract available


  126. EDER S, Beohou E, Labopin M, Sanz J, et al
    Thiotepa-based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia - a survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Am J Hematol. 2016 Sep 27. doi: 10.1002/ajh.24567.
    PubMed     Text format     Abstract available



  127. Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia.
    Am J Hematol. 2016;91:965.
    PubMed     Text format    


    August 2016
  128. CORTES JE, Khoury HJ, Kantarjian HM, Lipton JH, et al
    Long-term Bosutinib For Chronic Phase Chronic Myeloid Leukemia After Failure of Imatinib Plus Dasatinib and/or Nilotinib.
    Am J Hematol. 2016 Aug 17. doi: 10.1002/ajh.24536.
    PubMed     Text format     Abstract available


  129. ESTEY E
    Acute myeloid leukemia: 2016 Update on risk-stratification and management.
    Am J Hematol. 2016;91:824-46.
    PubMed     Text format     Abstract available


    July 2016
  130. KUMAR AJ, Gimotty PA, Gelfand J, Buck G, et al
    Delays in Post-Remission Chemotherapy for Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia are Associated with Inferior Outcomes in Patients who Undergo Allogeneic Transplant: An Analysis from ECOG 2993/MRC UK ALLXII.
    Am J Hematol. 2016 Jul 28. doi: 10.1002/ajh.24497.
    PubMed     Text format     Abstract available


  131. JAIN P, Kanagal-Shamanna R, Wierda W, Keating M, et al
    Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia.
    Am J Hematol. 2016 Jul 28. doi: 10.1002/ajh.24496.
    PubMed     Text format    


  132. MOLICA S, Shanafelt TD, Giannarelli D, Gentile M, et al
    The chronic lymphocytic leukemia international prognostic index (CLL-IPI) predicts time to first treatment in early CLL: Independent Validation in a Prospective Cohort of Early Stage Patients.
    Am J Hematol. 2016 Jul 27. doi: 10.1002/ajh.24493.
    PubMed     Text format     Abstract available


  133. AGBAY RL, Jain N, Loghavi S, Medeiros LJ, et al
    Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Am J Hematol. 2016 Jul 14. doi: 10.1002/ajh.24473.
    PubMed     Text format     Abstract available


  134. FLINN IW, Ruppert AS, Harwin W, Waterhouse D, et al
    A Phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia (CLL).
    Am J Hematol. 2016 Jul 7. doi: 10.1002/ajh.24468.
    PubMed     Text format     Abstract available


    June 2016
  135. DUBUC AM, Davids MS, Pulluqi M, Pulluqi O, et al
    FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpG-stimulated Chronic Lymphocytic Leukemia (CLL).
    Am J Hematol. 2016 Jun 24. doi: 10.1002/ajh.24452.
    PubMed     Text format     Abstract available


  136. PATNAIK MM, Tefferi A
    Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management.
    Am J Hematol. 2016;91:631-42.
    PubMed     Text format     Abstract available


  137. KUMAR AJ, Vassilev P, Loren AW, Luger SM, et al
    Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLI.
    Am J Hematol. 2016;91:426-9.
    PubMed     Text format     Abstract available


  138. HAMILTON BK, Visconte V, Jia X, Tabarroki A, et al
    Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations.
    Am J Hematol. 2016;91:406-9.
    PubMed     Text format     Abstract available


  139. CUNNINGHAM I, Kohno B
    18 FDG-PET/CT: 21st century approach to leukemic tumors in 124 cases.
    Am J Hematol. 2016;91:379-84.
    PubMed     Text format     Abstract available


    May 2016
  140. SHAH NP, Rousselot P, Schiffer C, Rea D, et al
    Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
    Am J Hematol. 2016 May 19. doi: 10.1002/ajh.24423.
    PubMed     Text format     Abstract available


  141. RYTTING ME, Jabbour EJ, Jorgensen JL, Ravandi F, et al
    Final results of a single institution experience with a pediatric-based regimen, the augmented berlin-frankfurt-munster (ABFM), in adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL), and comparison to the hyper-CVAD regimen.
    Am J Hematol. 2016 May 14. doi: 10.1002/ajh.24419.
    PubMed     Text format     Abstract available


  142. BADAR T, Handisides DR, Benito JM, Richie MA, et al
    A Phase I Study of Evofosfamide, an Investigational Hypoxia-Activated Prodrug, in Patients with Advanced Leukemia.
    Am J Hematol. 2016 May 11. doi: 10.1002/ajh.24415.
    PubMed     Text format     Abstract available


  143. WOLACH O, Stevenson KE, Wadleigh M, DeAngelo DJ, et al
    Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission.
    Am J Hematol. 2016 May 6. doi: 10.1002/ajh.24410.
    PubMed     Text format     Abstract available



  144. Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT).
    Am J Hematol. 2016;91:E301.
    PubMed     Text format    


  145. KONUMA T, Tsukada N, Kanda J, Uchida N, et al
    Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older.
    Am J Hematol. 2016;91:E284-92.
    PubMed     Text format     Abstract available


  146. ELALA YC, Lasho TL, Gangat N, Finke C, et al
    Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia.
    Am J Hematol. 2016;91:503-6.
    PubMed     Text format     Abstract available


  147. KOMROKJI RS, Kulasekararaj A, Al Ali NH, Kordasti S, et al
    Autoimmune diseases and myelodysplastic syndromes.
    Am J Hematol. 2016;91:E280-3.
    PubMed     Text format     Abstract available


  148. CEPPI F, Weitzman S, Woessmann W, Davies K, et al
    Safety and efficacy of intrathecal rituximab in children with B cell lymphoid CD20+ malignancies: An international retrospective study.
    Am J Hematol. 2016;91:486-91.
    PubMed     Text format     Abstract available


  149. HEXNER EO, Luger SM, Reshef R, Jeschke GR, et al
    Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment.
    Am J Hematol. 2016;91:453-60.
    PubMed     Text format     Abstract available


    April 2016
  150. EGAN D, Radich J
    Monitoring Disease Burden in Chronic Myeloid Leukemia: Past, Present, and Future.
    Am J Hematol. 2016 Apr 5. doi: 10.1002/ajh.24381.
    PubMed     Text format     Abstract available


  151. FRIEDMAN DR, Sibley AB, Owzar K, Chaffee KG, et al
    Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: A multi-institutional study.
    Am J Hematol. 2016 Apr 2. doi: 10.1002/ajh.24376.
    PubMed     Text format     Abstract available


    March 2016
  152. NABHAN C, Chaffee KG, Slager SL, Galanina N, et al
    Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemia.
    Am J Hematol. 2016 Mar 25. doi: 10.1002/ajh.24374.
    PubMed     Text format     Abstract available


  153. GUGLIOTTA G, Castagnetti F, Breccia M, Gozzini A, et al
    Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia.
    Am J Hematol. 2016 Mar 11. doi: 10.1002/ajh.24362.
    PubMed     Text format     Abstract available


  154. CHANTEPIE SP, Parienti JJ, Salaun V, Benabed K, et al
    The prognostic value of hematogones in patients with acute myeloid leukemia.
    Am J Hematol. 2016 Mar 2. doi: 10.1002/ajh.24350.
    PubMed     Text format     Abstract available


  155. BERNARDI M, Carrabba M, Messina C, Milani R, et al
    Elderly patients > 65 years of age with acute myeloid leukemia and normal karyotype benefit from intensive therapeutic programs.
    Am J Hematol. 2016 Mar 1. doi: 10.1002/ajh.24345.
    PubMed     Text format    


  156. SEFTEL MD, Neuberg D, Zhang MJ, Wang HL, et al
    Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission.
    Am J Hematol. 2016;91:322-9.
    PubMed     Text format     Abstract available


  157. PATNAIK MM, Lasho TL, Finke CM, Pardanani A, et al
    Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis.
    Am J Hematol. 2016;91:E12-4.
    PubMed     Text format    


  158. DEOTARE U, Yee KW, Le LW, Porwit A, et al
    Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-Color flow cytometry diagnosis and HyperCVAD therapy.
    Am J Hematol. 2016;91:283-6.
    PubMed     Text format     Abstract available


    February 2016
  159. PANERO J, Alves-Paiva RM, Roisman A, Santana-Lemos BA, et al
    Acquired TERT promoter mutations stimulate TERT transcription in mantle cell lymphoma.
    Am J Hematol. 2016 Feb 6. doi: 10.1002/ajh.24324.
    PubMed     Text format     Abstract available


  160. JABBOUR E, Kantarjian H
    Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
    Am J Hematol. 2016;91:252-265.
    PubMed     Text format     Abstract available


  161. DINARDO CD, Garcia-Manero G, Pierce S, Nazha A, et al
    Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    Am J Hematol. 2016;91:227-232.
    PubMed     Text format     Abstract available


  162. TAVITIAN S, Denis A, Vergez F, Berard E, et al
    Impact of obesity in favorable-risk AML patients receiving intensive chemotherapy.
    Am J Hematol. 2016;91:193-8.
    PubMed     Text format     Abstract available


    January 2016
  163. BERNASCONI P, Farina M, Boni M, Dambruoso I, et al
    Therapeutically targeting self-reinforcing leukemic niches in acute myeloid leukemia (AML): A worthy endeavour?
    Am J Hematol. 2016 Jan 28. doi: 10.1002/ajh.24312.
    PubMed     Text format     Abstract available


  164. ROOS-WEIL D, Nguyen-Khac F, Bernard OA
    Chronic lymphocytic leukemia: Time to go past genomics?
    Am J Hematol. 2016 Jan 22. doi: 10.1002/ajh.24301.
    PubMed     Text format     Abstract available


  165. WU B, Harrison G, Wang E
    "Hairy" cells in acute promyelocytic leukemia: Excess myeloperoxidase with formation of needle-shaped crystalline projections on the cytochemical stain in a case with variant morphology.
    Am J Hematol. 2016 Jan 22. doi: 10.1002/ajh.24298.
    PubMed     Text format    


  166. SALE S, Fumi M, Pancione Y, Parente D, et al
    The fortuitous diagnosis of Burkitt lymphoma in a patient with chronic myelomonocytic leukemia.
    Am J Hematol. 2016 Jan 22. doi: 10.1002/ajh.24297.
    PubMed     Text format    


  167. VITALE C, Jabbour E, Lu X, Yabe M, et al
    Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia.
    Am J Hematol. 2016 Jan 22. doi: 10.1002/ajh.24302.
    PubMed     Text format    


  168. SHORT NJ, Kantarjian HM, Jabbour EJ, O'Brien SM, et al
    Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia.
    Am J Hematol. 2016 Jan 21. doi: 10.1002/ajh.24296.
    PubMed     Text format     Abstract available


  169. JAIN P, Tang G, Huh YO, Yin CC, et al
    Philadelphia - positive dimorphic blasts in mixed-phenotype acute leukemia with TET2 mutation.
    Am J Hematol. 2016 Jan 21. doi: 10.1002/ajh.24295.
    PubMed     Text format    


  170. FORDHAM NJ, Stern S, Swansbury J, Bain BJ, et al
    The distinctive micromegakaryocytes of transformed chronic myeloid leukemia.
    Am J Hematol. 2016 Jan 9. doi: 10.1002/ajh.24290.
    PubMed     Text format    


  171. JABBOUR E
    Chronic myeloid leukemia: First-line drug of choice.
    Am J Hematol. 2016;91:59-66.
    PubMed     Text format     Abstract available


  172. FREY NV, Porter DL
    CAR T-cells merge into the fast lane of cancer care.
    Am J Hematol. 2016;91:146-50.
    PubMed     Text format     Abstract available


  173. TEFFERI A
    Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
    Am J Hematol. 2016;91:50-8.
    PubMed     Text format     Abstract available


    December 2015
  174. MANGARU Z, Shetty S, Visconte V, Liu HD, et al
    Acute myeloid leukemia with inv(16)(p13.1q22), abnormal eosinophils, and absence of peripheral blood and bone marrow blasts.
    Am J Hematol. 2015 Dec 30. doi: 10.1002/ajh.24289.
    PubMed     Text format    


  175. ELLIOTT MA, Tefferi A
    Chronic Neutrophilic Leukemia 2016: Update on diagnosis, molecular genetics, prognosis and management.
    Am J Hematol. 2015 Dec 23. doi: 10.1002/ajh.24284.
    PubMed     Text format     Abstract available


  176. RAI KR, Jain P
    Chronic lymphocytic leukemia (CLL) - Then and Now.
    Am J Hematol. 2015 Dec 21. doi: 10.1002/ajh.24282.
    PubMed     Text format     Abstract available


  177. CAMPUZANO-ZULUAGA G, Deutsch Y, Salzberg M, Gomez A, et al
    Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?
    Am J Hematol. 2015 Dec 10. doi: 10.1002/ajh.24271.
    PubMed     Text format     Abstract available


  178. AOKI J, Kanamori H, Tanaka M, Yamasaki S, et al
    Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia.
    Am J Hematol. 2015 Dec 10. doi: 10.1002/ajh.24270.
    PubMed     Text format     Abstract available


  179. YU H, Wertheim G, Shankar S, Paessler M, et al
    Marked eosinophilia masking B lymphoblastic leukemia.
    Am J Hematol. 2015 Dec 10. doi: 10.1002/ajh.24266.
    PubMed     Text format    


  180. ZENT CS, Wang XV, Ketterling RP, Hanson CA, et al
    A Phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: A Trial of the ECOG-ACRIN Cancer Research Group (E1908).
    Am J Hematol. 2015 Dec 10. doi: 10.1002/ajh.24265.
    PubMed     Text format     Abstract available


  181. MOLLER T, Moser C, Adamsen L, Rugaard G, et al
    Early warning and prevention of pneumonia in acute leukemia by patient education, spirometry, and positive expiratory pressure: A randomized controlled trial.
    Am J Hematol. 2015 Dec 10. doi: 10.1002/ajh.24262.
    PubMed     Text format     Abstract available


    November 2015
  182. KANTARJIAN H
    Acute Myeloid Leukemia- Major Progress over Four Decades, and Glimpses into the Future.
    Am J Hematol. 2015 Nov 24. doi: 10.1002/ajh.24246.
    PubMed     Text format    


  183. GAMBACORTI-PASSERINI C, Aroldi A, Cordani N, Piazza R, et al
    Chronic myeloid leukemia: Second-line drugs of choice.
    Am J Hematol. 2015 Nov 20. doi: 10.1002/ajh.24247.
    PubMed     Text format     Abstract available


  184. SHAH NP, Wallis N, Farber HW, Mauro MJ, et al
    Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.
    Am J Hematol. 2015;90:1060-4.
    PubMed     Text format     Abstract available


    October 2015
  185. MORI S, Vagge E, le Coutre P, Abruzzese E, et al
    Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study.
    Am J Hematol. 2015;90:910-4.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: